Status:
NOT_YET_RECRUITING
Technology dRiven Enhancement to Engage & Connect
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Depression
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
This study will investigate whether an intervention that includes remotely delivered therapy sessions and a digital mental health app, compared to only remotely delivered therapy reduces late-life dep...
Detailed Description
Depression in mid- and late-life is characterized with reduced functions of the reward system. The investigators designed a psychotherapy that aims to improve reward functions through engagement in pl...
Eligibility Criteria
Inclusion
- Adults aged 50-80
- Capacity to provide consent for research assessment and treatment.
- Significant depression, i.e., PHQ-9 ≥10 (moderate severity of symptoms)
- Mini Mental Status Exam (MMSE) equal or greater than a score of 23.
- Off antidepressants or on stable dose for 8 weeks and do not intend to change the dose in the next 10 weeks, without individual psychotherapy services during the study period.
Exclusion
- Intent or plan to commit suicide in the near future.
- Inability to communicate in English.
- History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, generalized anxiety disorder, specific phobia, or antisocial or borderline personality disorder.
- Neurological disorders (dementias, amnestic and multidomain Mild Cognitive Impairment, Parkinson's disease, epilepsy, etc.).
- Acute or severe medical illness in the past 3 months (metastatic cancer, multiple sclerosis, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction, cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease, etc.) that may be the primary cause depressive symptoms, influence brain systems of interest, or impact ability to participate in the study.
- For MRI only: Contraindications to MRI scanning including cardiac pacemaker, heart valve replacement, vascular stent, insulin pump, cochlear implant, any other metallic biomedical implant contraindicating to MRI, and claustrophobia.
Key Trial Info
Start Date :
March 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06910683
Start Date
March 1 2026
End Date
March 1 2028
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medicine
New York, New York, United States, 10065